BioCryst Pharmaceuticals (BCRX) closed the last trading session at $7.95, gaining 4.2% over the past four weeks, but there ...

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on BioCryst (BCRX – Research Report) today. The company’s shares opened today at $7.62. Ahmad covers the Healthcare sector, ...

BioCryst Pharmaceuticals (BCRX) came out with a quarterly loss of $0.07 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.19 per share a year ago. These figures are ...

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) have earned a consensus recommendation of “Moderate ...

A Durham company says its drug is pacing for over $400 million in revenue this year. The goal is $1 billion.

Evercore ISI analyst Liisa Bayko maintained a Buy rating on BioCryst (BCRX – Research Report) today and set a price target of $10.00. The ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Short interest in BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) decreased during the last reporting period, falling from 23.23M to 22.53M. This put 10.98% of the company's publicly available shares ...